A renaissance for antisense oligonucleotide drugs in neurology: Exon skipping breaks new ground

Archives of Neurology

Volumn 66, Issue 1, 2009, Pages 32-38

  Yokota, Toshifumi ^a   Takeda, Shin'ichi ^b   Lu, Qi Long ^c   Partridge, Terence A ^a   Nakamura, Akinori ^b   Hoffman, Eric P ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; DYSTROPHIN; MESSENGER RNA;

DUCHENNE MUSCULAR DYSTROPHY; EXON; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; NUCLEOTIDE SEQUENCE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; RNA BINDING; RNA SPLICING; RNA TRANSLATION;

DNA; DYSTROPHIN; EXONS; GENE TARGETING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; NERVOUS SYSTEM DISEASES; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 58449122870     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.540     Document Type: Review

References (19)

1. Spiegelman WG, Reichardt LF, Yaniv M, Heinemann SF, Kaiser AD, Eisen H. Bidirectional transcription and the regulation of phage lambda repressor synthesis. Proc Natl Acad Sci U S A. 1972;69(11):3156-3160.
2. Kumar M, Carmichael GG. Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol Mol Biol Rev. 1998;62(4):1415- 1434.
3. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature. 2002;418(6896):430-434.
4. Kim SK, Wold BJ. Stable reduction of thymidine kinase activity in cells expressing high levels of anti-sense RNA. Cell. 1985;42(1):129-138.
5. Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006;2(1):e1. doi:10.1371/journal.ppat.0020001.
6. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928.
7. Hoffman EP. Skipping toward personalized molecular medicine. N Engl J Med. 2007;357(26):2719-2722.
8. Dunckley MG, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 1998;7(7):1083-1090.
9. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007;357(26):2677-2686.
10. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest. 2007;117(12):3952-3957.
11. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007;5(4):e73. doi:10.1371/journal.pbio.0050073.
12. Asparuhova MB, Marti G, Liu S, Serhan F, Trono D, Schumperli D. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med. 2007;9(5):323-334.
13. Kesari A, Pirra LN, Bremadesam L, et al. Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat. 2008;29(5):728-737.
14. Yokota T, Duddy W, Partridge T. Optimizing exon skipping therapies for DMD. Acta Myol. 2007;26(3):179-184.
15. Covone AE, Lerone M, Romeo G. Genotype-phenotype correlation and germline mosaicism in DMD/BMD patients with deletions of the dystrophin gene. Hum Genet. 1991;87(3):353-360.
16. Talkop UA, Klaassen T, Piirsoo A, et al. Duchenne and Becker muscular dystrophies: an Estonian experience. Brain Dev. 1999;21(4):244-247.
17. Menhart N. Hybrid spectrin type repeats produced by exon-skipping in dystrophin. Biochim Biophys Acta. 2006;1764(6):993-999.
18. Béroud C, Tuffery-Giraud S, Matsuo M, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat. 2007;28(2):196-202.
19. Nakamura A, Yoshida K, Fukushima K, et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci. 2008;15(7):757-763.